AstraZeneca divests rights for Losec to Cheplapharm
AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm).
-
-
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
-
Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
AstraZeneca today announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C)
-
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
AstraZeneca has agreed to divest the prescription medicine rights to Nexium(esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
-
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
-
ASTRAZENECA SHARPENS FOCUS ON MAIN THERAPY AREAS THROUGH AGREEMENT WITH GASTROENTEROLOGY SPECIALIST TILLOTTS PHARMA FOR ENTOCORT
AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis.
-
NYTT BEHANDLINGSALTERNATIV FÖR FÖRSTOPPNING ORSAKAD AV OPIOIDER
Nu finns AstraZenecas läkemedel Moventig® (naloxegol) tillgängligt i Sverige, som första land i Europa. Läkemedlet är avsett för att behandla förstoppning orsakad av smärtlindrande läkemedel innehållande opioider hos vuxna patienter som upplevt otillräcklig effekt av laxermedel
-
MOVENTIG (naloxegol) GODKÄNT FÖR BEHANDLING AV OPIOIDORSAKAD FÖRSTOPPNING
AstraZeneca meddelar att Moventig (naloxegol) har beviljats marknadsföringstillstånd av Europeiska Kommissionen (EC) för behandling av opiodinducerad förstoppning av vuxna patienter som har haft otillräcklig respons på laxermedel. Läkemedlet är den första orala, perifert verkande mu-opioidreceptorantagonisten med en gång om dagen-dosering (PAMORA) som godkänns inom EU.
-
Jury verdict favours AstraZeneca in Nexium antitrust litigation
AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
AstraZeneca is pleased with the jury’s verdict. The Company has always maintained that the plaintiffs’ alle -
ASTRAZENECA ENTERS AGREEMENT WITH HANMI PHARMACEUTICAL AND AMNEAL PHARMACEUTICALS IN
AstraZeneca today announced it has entered into an agreement with Hanmi Pharmaceutical and affiliates (“Hanmi”) and its US marketing partner Amneal Pharmaceuticals (“Amneal”) to resolve certain issues and appeal others in US Nexium patent litigation regarding Hanmi’s Esomeprazole Strontium 505(b)2 NDA product.
-
AstraZeneca och Pfizer ingår avtal om receptfritt Nexium – AstraZeneca höjer resultatprognosen för 2012
Introduktionen av receptfritt Nexium 20 mg planeras till 2014, förutsatt myndigheternas godkännande
-
Läkemedelsverket ger godkänt för ny förebyggande behandling av hjärt/kärlsjukdom
Läkemedelsverket har godkänt Axanum (acetylsalicylsyra/esomeprazol). Axanum är det första kombinationsläkemedlet i en fast doskombination av acetylsalicylsyra (ASA), som förebygger hjärt/kärlsjukdomar som hjärtinfarkt och stroke, och esomeprazol som förebygger magsår och blödningar från tolvfingertarmen.
Visa mer
Loading...